Not yet recruiting
Efficacy and Safety of the Angionix Balloon in Patients With Coronary Artery Disease Undergoing PTCA
NCT07869602· Yonsei University· Source
Contact: Yongcheol Kim, MD.,PhD
Not yet recruiting
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
NCT07730840· Phase 3· Asan Medical Center· Source
Contact: Hyun Goo Kang, MD, PhD
Recruiting
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
NCT07741721· Chonnam National University Hospital· Source
Contact: Min Chul Kim, MD, PhD
Recruiting
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
NCT07733765· Phase 3· Pfizer· Source
Not yet recruiting
Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation
NCT07486739· Seoul National University Hospital· Source
Contact: Jung Rae-Young
Active, not recruiting
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
NCT07481604· Phase 2· Aribio Lab Co., Ltd.· Source
Recruiting
LEXURE for Post-Stroke Aphasia
NCT07570264· Nunaps Inc· Source
Contact: Hyun Goo Kang, MD, PhD
Recruiting
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
NCT07533006· Phase 2· Eli Lilly and Company· Source
Contact: Jin Park (principal investigator)
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07363694· Phase 2/3· Pfizer· Source
Recruiting
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
NCT07687706· Phase 3· Hanyang University Guri Hospital· Source
Contact: Seong-Ho Koh, MD, PhD
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, Inc.
Recruiting
Smart Angioplasty Research Team-Coronary CT Angiography Versus Standard Care as Follow-up Strategies in High-Risk Patients After PCI (SMART-CARE)
NCT07009418· Samsung Medical Center· Source
Contact: Yisik Kim, MD, PhD
Recruiting
Late-lumen Changes After Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stents in De Novo Coronary Lesions
NCT06954714· Chonnam National University Hospital· Source
Contact: Yi Sik Kim, MD, PhD
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168· Phase 2· Daiichi Sankyo· Source
Recruiting
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
NCT07002164· Chonnam National University Hospital· Source
Contact: Youngkeun Ahn, Professor
Recruiting
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
NCT06757764· Phase 4· Asan Medical Center· Source
Contact: Hyun Goo Kang, MD, PhD
Recruiting
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
NCT06962098· Phase 2· Aptabio Therapeutics, Inc.· Source
Contact: Won Kim
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· Phase 3· Pfizer· Source
Recruiting
Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
NCT06724653· Chungnam National University Hospital· Source
Contact: Jiyeonn Lee
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866· Phase 3· Amgen· Source
Active, not recruiting
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· Phase 3· Amgen· Source
Recruiting
OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
NCT06227754· Chonnam National University Hospital· Source
Contact: Yi Sik Kim, MD, PhD
Recruiting
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
NCT06246123· Eisai Korea Inc.· Source
Contact: Serena SoYoun Kwon
Active, not recruiting
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
NCT05995600· Phase 4· Seoul National University Hospital· Source
Active, not recruiting
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
NCT06088121· Advanced Technology & Communications· Source
Contact: AT&C
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· Phase 3· Eli Lilly and Company· Source
Contact: Jin Park (principal investigator)
Recruiting
OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation
NCT05418556· Phase 4· Asan Medical Center· Source
Contact: Yisik Kim, MD
Active, not recruiting
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT05144854· Phase 3· Ono Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
NCT04725994· Phase 1/2· Idience Co., Ltd.· Source
Active, not recruiting
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634· Phase 2· MitoImmune Therapeutics· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· Phase 3· Incyte Corporation· Source
Active, not recruiting
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
NCT05673772· Phase 2· Kyungpook National University Hospital· Source
Active, not recruiting
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599· Phase 1/2· Genmab· Source